We found that Ki16425 inhibited the ability of LPA to induce migration in both the E10 and SCC-9 cells, which, in view of our failure to demonstrate expression of LPAR1 protein, is additional support for LPAR3 being involved.
These strengths were counterbalanced by a poor test-retest reliability and criterion validity of the ASQ, probably because of methodological shortcomings, and failure to demonstrate effects of socio-economic status.
The recent failure of MF Global demonstrates that this is entirely possible.
Lack of a large enough number of RCTs, especially for phase III, could be a possible explanation of the failure to demonstrate significance, although the possible efficacy of taxane or platinum was suggested consistently.
Despite a compelling series of failures to demonstrate the efficacy of antithrombin for treating sepsis, severe sepsis and septic shock, the present randomized, controlled, multicenter trial of the effects of antithrombin on DIC in patients with sepsis, severe sepsis and septic shock succeeded in achieving the primary study end point of improving the rate of recovery from DIC.
Failure to demonstrate effectiveness of antithrombin may be due to the heterogeneity of the patient population investigated.
In view of the failure to demonstrate interaction between CD40 and C4BP (see results), we carried out an additional experiment where C4BP was immobilised on the chip surface.
A possible explanation of the failure to demonstrate enhanced collagen synthesis following exercise, despite augmented collagen type I and III transcription, is that SUV calculations are not sensitive enough to detect minor changes in collagen synthesis.
The failure to demonstrate noninferiority of the lower dose is particularly important in the curative setting of previously untreated localized disease.
Further, the failure to demonstrate efficacy of everolimus in the EVOLVE study has highlighted the potential importance of appropriate patient selection.
